2023
Eligibility for Cardiovascular Risk Reduction Therapy in the United States Based on SELECT Trial Criteria: Insights From the National Health and Nutrition Examination Survey
Lu Y, Liu Y, Jastreboff A, Khera R, Ndumele C, Rodriguez F, Watson K, Krumholz H. Eligibility for Cardiovascular Risk Reduction Therapy in the United States Based on SELECT Trial Criteria: Insights From the National Health and Nutrition Examination Survey. Circulation Cardiovascular Quality And Outcomes 2023, 17: e010640. PMID: 37950677, PMCID: PMC10782930, DOI: 10.1161/circoutcomes.123.010640.Peer-Reviewed Original Research
2021
Rationale and pathways forward in the implementation of coronary artery calcium-based enrichment of randomized trials
Cainzos-Achirica M, Anugula D, Mszar R, Grandhi G, Patel K, Bittencourt M, Blankstein R, Blaha M, Blumenthal R, Ray K, Bhatt D, Nasir K. Rationale and pathways forward in the implementation of coronary artery calcium-based enrichment of randomized trials. American Heart Journal 2021, 243: 54-65. PMID: 34587511, DOI: 10.1016/j.ahj.2021.09.006.Peer-Reviewed Original ResearchConceptsCoronary artery calciumRandomized Controlled TrialsPrognostic enrichmentCoronary artery calcium scoreCoronary artery calcium dataAdd-on therapyRisk reduction therapyFood and Drug AdministrationComputed tomography imagesArtery calciumCardiovascular riskRandomized trialsEnrichment paradigmDrug AdministrationPrimary preventionTomography imagesRCT participantsTherapyTrialsLogistical barriersRisk
2017
HIV/HCV coinfection and the risk of cardiovascular disease: A meta‐analysis
Osibogun O, Ogunmoroti O, Michos E, Spatz E, Olubajo B, Nasir K, Madhivanan P, Maziak W. HIV/HCV coinfection and the risk of cardiovascular disease: A meta‐analysis. Journal Of Viral Hepatitis 2017, 24: 998-1004. PMID: 28502092, DOI: 10.1111/jvh.12725.Peer-Reviewed Original ResearchConceptsHIV/HCV coinfectionHCV coinfectionHazard ratioCardiovascular diseaseHIV monoinfectionCVD riskHepatitis C virus coinfectionTraditional CVD risk factorsC virus coinfectionImproved antiretroviral therapyAdjusted hazard ratioCVD risk factorsRisk reduction therapyCongestive heart failureCoronary artery diseaseHuman immunodeficiency virusIncreased inflammatory responseRandom-effects modelWeb of ScienceHCV individualsAntiretroviral therapyCohort studyCVD outcomesArtery diseaseHeart failure
2005
Patterns of reduced nipple aspirate fluid production and ductal lavage cellularity in women at high risk for breast cancer
Higgins SA, Matloff ET, Rimm DL, Dziura J, Haffty BG, King BL. Patterns of reduced nipple aspirate fluid production and ductal lavage cellularity in women at high risk for breast cancer. Breast Cancer Research 2005, 7: r1017. PMID: 16280052, PMCID: PMC1410733, DOI: 10.1186/bcr1335.Peer-Reviewed Original ResearchConceptsHigh-risk womenFluid-yielding ductsPrevious multicenter trialsMulticenter trialBreast cancerDuctal lavageLavage cellularityPresent seriesNAF productionSelective estrogen receptor modulatorsRisk-reducing therapiesRisk reduction therapyBRCA germline mutationsEstrogen receptor modulatorsBRCA-positive womenBreast cancer developmentEvaluation of abnormalitiesPostmenopausal statusHealthy womenBreast fluidIntraductal approachReceptor modulatorsRelative riskDuctal orificeReduction therapy
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply